Gabriela S. Hobbs
A5065595440- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Kruppel-like factors research
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- Acute Lymphoblastic Leukemia research
- Histone Deacetylase Inhibitors Research
- Palliative Care and End-of-Life Issues
- Cancer survivorship and care
- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- Hemoglobinopathies and Related Disorders
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Mast cells and histamine
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Platelet Disorders and Treatments
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Sepsis Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Cytokine Signaling Pathways and Interactions
Massachusetts General Hospital
2016-2025
Harvard University
2016-2025
Leukemia Research Foundation
2025
AbbVie (United Kingdom)
2023
Novartis (Switzerland)
2023
Pfizer (United States)
2023
Incyte (United States)
2023
MorphoSys (Germany)
2023
CTI BioPharma (Italy)
2023
Jazz Pharmaceuticals (United States)
2020
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, blast phase) usually diagnosed chronic phase. Tyrosine kinase inhibitor (TKI) therapy highly effective first-line treatment option for all patients with newly phase (CP-CML). The selection TKI should be based on risk score,...
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, blast phase) usually diagnosed chronic phase. Tyrosine kinase inhibitor therapy highly effective first-line treatment option for all patients with newly phase CML. This manuscript discusses recommendations outlined NCCN...
Some cancers originate from a single mutation event in cell. Blood known as myeloproliferative neoplasms (MPNs) are thought to when driver is acquired by hematopoietic stem cell (HSC). However, the first occurs individuals and how it affects behavior of HSCs their native context not known. Here we quantified effect JAK2-V617F on self-renewal differentiation dynamics treatment-naive with MPNs reconstructed lineage histories individual using somatic patterns. We found that mutations occurred...
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia are a heterogeneous group clonal blood disorders characterized by an overproduction cells. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as result meetings convened multidisciplinary panel with expertise MPN, the goal providing recommendations management adults. include diagnostic workup, risk...
Immunosuppression is associated with a variety of idiopathic clinical syndromes that may have infectious causes. It has been hypothesized the cord colitis syndrome, complication umbilical-cord hematopoietic stem-cell transplantation, in origin.
Shared decision-making is an important component of patient-centered care and associated with improved outcomes. To the authors' knowledge, little known concerning extent predictors involvement a patient's family in decisions regarding cancer treatments.
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV ET characterized by significant thrombohemorrhagic complications high risk transformation to MF acute myeloid leukemia. The diagnosis management has evolved since identification mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss recommendations outlined Guidelines for...
<h3>Importance</h3> Patients with acute myeloid leukemia (AML) receiving intensive chemotherapy experience substantial decline in their quality of life (QOL) and mood during hospitalization for induction often receive aggressive care at the end (EOL). However, role specialty palliative improving QOL this population is currently unknown. <h3>Objective</h3> To assess effect integrated oncology (IPC) on patient-reported EOL outcomes patients AML. <h3>Design, Setting, Participants</h3> We...
Background and purpose Combining inhibitors of vascular endothelial growth factor the programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple cancers, but disease-specific agent-specific mechanisms benefit remain unclear. We examined defined when combining regorafenib (a multikinase antivascular receptor inhibitor) with PD1 blockade murine hepatocellular carcinoma (HCC) models. Basic procedures used orthotopic models HCC mice liver damage to test effects...
Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation abnormal mast cells and their accumulation in skin and/or various extracutaneous organs. Systemic mastocytosis most common form diagnosed adults, characterized by cell infiltration one or more organs (with without involvement). The identification KIT D816V mutation emergence novel targeted therapies have significantly improved diagnosis treatment systemic mastocytosis. However, certain aspects clinical...
Abstract Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without (non-HCT) (1377 was analyzed Cox proportional hazards model. Survival analysis stratified by Dynamic International Prognostic Scoring System (DIPSS) revealed that first year of treatment arm assignment, due to upfront risk transplant-related...
The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer are poorly understood.We performed a prospective cohort study adults solid-organ or hematologic cancers to evaluate anti-SARS-CoV-2 immunoglobulin A/M/G spike antibodies, neutralization, ≥ 7 days following two doses mRNA-1273, BNT162b2, one dose Ad26.COV2.S. We analyzed responses by multivariate regression included data from 1,638 healthy controls, previously reported, for comparison.Between April July 2021,...
Abstract Splenomegaly is the clinical hallmark of myelofibrosis. at time allogeneic hematopoietic cell transplantation (HCT) associated with graft failure and poor function. Strategies to reduce spleen size before HCT especially after Janus kinase (JAK) inhibition represent unmet needs in field. Here, we leveraged a global collaboration investigate safety efficacy splenic irradiation as part platform for patients We included 59 patients, receiving within median 2 weeks (range, 0.9–12 weeks)...
Interferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years. The initial use of interferons was limited due difficulties administration a significant toxicity profile. Many these shortcomings were addressed by covalently binding polyethylene glycol the interferon structure, which increases stability, prolongs activity, reduces immunogenicity molecule. In current therapeutic...
Abstract Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, safety add-on PI3Kδ inhibitor parsaclisib for primary secondary myelofibrosis to ruxolitinib. Eligible remained on a stable ruxolitinib dose received 10 20 mg, once...
The NCCN Guidelines for Chronic Myeloid Leukemia (CML) provide recommendations the management of chronic-phase and advanced-phase CML in adult patients. median age disease onset is 67 years. However, because occurs all groups, clinical care teams should be prepared to address issues relating fertility pregnancy with patients who are reproductive at time diagnosis. relatively rare children there no evidence-based pediatric population. These Insights discuss special considerations during
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders the hematopoietic system collectively known as Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs). The diagnosis management patients with MPNs have evolved since identification mutations that activate JAK pathway (JAK2, CALR, MPL mutations) development targeted therapies has resulted in significant improvements disease-related symptoms quality life. This...
Abstract Background Older patients (≥60 years) with acute myeloid leukemia (AML) face difficult decisions regarding treatment “intensive” chemotherapy that carries significant toxicity for a small chance of cure versus “nonintensive” to control the disease, but fewer side effects. However, studies how these understand risks and benefits such treatments are lacking. Methods We conducted longitudinal study older newly diagnosed AML assessing patients’ (n = 100) oncologists’ 11) perceptions...